Janssen’s IMBRUVICA® (ibrutinib) Receives Positive CHMP Opinion for Expanded Use in Previously Untreated Chronic Lymphocytic Leukaemia Patients
- EMEA Innovative Medicine
- Janssen’s IMBRUVICA® (ibrutinib) Receives Positive CHMP Opinion for Expanded Use in Previously Untreated Chronic Lymphocytic Leukaemia Patients
Janssen’s IMBRUVICA® (ibrutinib) Receives Positive CHMP Opinion for Expanded Use in Previously Untreated Chronic Lymphocytic Leukaemia Patients
- X (Twitter)
Copy link